ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) has received an average broker rating score of 1.00 (Strong Buy) from the three brokers that cover the company, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy rating.

Analysts have set a one year consensus price objective of $5.10 for the company and are expecting that the company will post ($0.17) earnings per share for the current quarter, according to Zacks. Zacks has also assigned ESSA Pharma an industry rank of 119 out of 265 based on the ratings given to its competitors.

Several equities research analysts have issued reports on EPIX shares. Bloom Burton reiterated a “buy” rating on shares of ESSA Pharma in a research report on Thursday, May 18th. Dawson James restated a “buy” rating on shares of ESSA Pharma in a report on Thursday, August 3rd. Zacks Investment Research upgraded shares of ESSA Pharma from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 18th. Finally, ValuEngine lowered shares of ESSA Pharma from a “sell” rating to a “strong sell” rating in a report on Wednesday, June 7th.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at

Shares of ESSA Pharma (NASDAQ:EPIX) traded up 2.2778% during trading on Monday, reaching $0.3682. 16,734 shares of the company traded hands. The stock’s market capitalization is $10.71 million. ESSA Pharma has a 12-month low of $0.25 and a 12-month high of $3.59. The firm’s 50-day moving average is $0.42 and its 200-day moving average is $1.67.

About ESSA Pharma

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor.

Get a free copy of the Zacks research report on ESSA Pharma (EPIX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for ESSA Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.